UNASSIGNED: Forty-two eyes of 38 cases with iris and ciliary body tumors imaged with UBM and AS SS-OCT between September 2018 and September 2023 were evaluated retrospectively.
UNASSIGNED: Of 42 eyes, 14 had melanoma, 14 iris pigment epithelial (IPE) cysts, 7 nevi, 3 Lisch nodules, 2 iris stromal cysts, 1 pars plana cysts, and 1 iris mammillations. An equivalent (100%) visualization of the anterior tumor margin was obtained with both techniques. Compared to AS SS-OCT, UBM was superior for posterior margin visualization in melanocytic tumors and IPE cysts. Bland-Altman plots demonstrated good agreement between UBM and AS SS-OCT for melanocytic tumors < 2.5 mm in base diameter and < 2 mm in thickness.
UNASSIGNED: Although, UBM is the gold standard for ciliary body and iridociliary tumors. AS SS-OCT should be considered as an excellent alternative to UBM, especially in minimally elevated iris lesions.
■回顾性评估了2018年9月至2023年9月间使用UBM和ASSS-OCT成像的38例虹膜和睫状体肿瘤的42只眼。
■42只眼睛,14人患有黑色素瘤,14虹膜色素上皮(IPE)囊肿,7nevi,3Lisch结节,2个虹膜基质囊肿,1个平面囊肿,和1个虹膜乳头。两种技术均获得了肿瘤前缘的等效(100%)可视化。与ASSS-OCT相比,UBM在黑素细胞肿瘤和IPE囊肿的后缘可视化方面优于UBM。Bland-Altman图表明,对于基底直径<2.5mm和厚度<2mm的黑素细胞肿瘤,UBM和ASSS-OCT之间具有良好的一致性。
■虽然,UBM是睫状体和虹膜睫状体肿瘤的黄金标准。SS-OCT应被视为UBM的优秀替代品,尤其是在最低限度的虹膜病变中。